drug_type
RELEVANT_DRUG
intervention_type
Biologic drug (antibody–drug conjugate)
drug_description
A HER2-targeted antibody–drug conjugate composed of a humanized anti-HER2 monoclonal antibody linked via an enzyme-cleavable linker to a topoisomerase I inhibitor payload; upon HER2 binding and internalization, linker cleavage releases the payload to inhibit topoisomerase I, causing DNA damage and tumor cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Injections
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 monoclonal antibody linked via an enzyme-cleavable linker to a topoisomerase I inhibitor. After binding HER2 on tumor cells and internalization, the linker is cleaved to release the payload, which inhibits topoisomerase I, inducing DNA damage and tumor cell death with HER2-targeted delivery.
drug_name
TQB2102 for injection
nct_id_drug_ref
NCT06115902